Streetbeat News

LXRX

Lexicon Pharmaceuticals, Inc.

https://www.lexpharma.com

Industry

Biotechnology

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Open

0.36

Mkt cap

132M

Volume

High

0.37

P/E Ratio

-0.58

52-wk high

2.59

Low

0.36

Div yield

N/A

52-wk low

0.28

Several US stocks recorded losses on Monday, including Scilex Holding Company, Canopy Growth Corporation, Nuvalent, DocGo, GigaCloud Technology, Eos Energy Enterprises, Unity Software, FingerMotion, Rumble, Butterfly Network, Couchbase, Caribou Biosciences, Moderna, Lexicon Pharmaceuticals, Wayfair, The Gap, Viking Therapeutics, AMC Entertainment Holdings, Tellurian, MINISO Group Holding, and Arm Holdings.

Portfolio Pulse from Lisa Levin

September 18, 2023 | 3:08 pm

Lexicon Pharmaceuticals has announced a series of presentations related to LX9211, its investigational drug for the treatment of diabetic peripheral neuropathic pain.

Portfolio Pulse from Benzinga Newsdesk

September 07, 2023 | 1:00 pm

Lexicon Pharmaceuticals is set to present analyses of its INPEFA clinical study results and changing patterns of heart failure diagnoses at the European Society of Cardiology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2023 | 1:06 pm

A post-hoc analysis of SOLOIST-WHF clinical data published in the Journal of the American College of Cardiology shows that Sotagliflozin significantly reduces the risk of hospital readmissions for heart failure. The risk reductions are approximately 50% for heart failure readmissions and for the composite of CV death and heart failure readmissions at 30- and 90-days following hospital discharge.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2023 | 1:05 pm

Insiders at Lexicon Pharmaceuticals, Gaia, and Superior Industries International have recently acquired shares in their respective companies. Lexicon Pharmaceuticals and Gaia reported wider-than-expected Q2 losses, while Superior Industries posted downbeat quarterly sales.

Portfolio Pulse from Lisa Levin

August 08, 2023 | 12:50 pm

Lexicon Pharmaceuticals reported Q2 losses of $(0.22) per share, missing the analyst consensus estimate of $(0.17) by 29.41%. This is a 37.5% decrease over losses from the same period last year. However, the company reported quarterly sales of $317.00K, beating the analyst consensus estimate of $70.00K by 352.86%, a 805.71% increase over sales from the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 04, 2023 | 2:33 pm

Several US stocks are trading lower in the pre-market session. Levi Strauss & Co. (LEVI) shares dipped 8.2% despite reporting upbeat Q2 earnings, as the company lowered its annual profit outlook. BioXcel Therapeutics (BTAI) shares fell 7.4% following the release of topline results for a Phase 3 trial of BXCL501 for Alzheimer's disease-related agitation. Senseonics Holdings (SENS) shares dropped 5.4% after reporting equity grants to employees. Varonis Systems (VRNS) shares declined 4.8%, Lexicon Pharmaceuticals (LXRX) shares fell 3.2%, and Riot Platforms (RIOT) shares slipped 2.5% after issuing production and operations updates.

Portfolio Pulse from Lisa Levin

July 07, 2023 | 10:48 am

Insiders at TransCode Therapeutics, Lexicon Pharmaceuticals, and Global Clean Energy Holdings have recently made significant purchases of their respective companies' shares. TransCode Therapeutics published new data supporting the use of TTX-MC138 for metastatic breast cancer treatment, Lexicon Pharmaceuticals announced the pricing of a $125 million public offering and concurrent private placement, and Global Clean Energy signed a $30 million USDA climate-smart commodities grant for its camelina project.

Portfolio Pulse from Lisa Levin

June 23, 2023 | 11:08 am

Insiders at Lexicon Pharmaceuticals, Avalo Therapeutics, and PEDEVCO have recently made significant stock purchases. Lexicon announced a $125 million public offering and concurrent private placement, Avalo posted a narrower-than-expected quarterly loss, and PEDEVCO expanded into Wyoming D-J Basin Codell Play.

Portfolio Pulse from Lisa Levin

June 21, 2023 | 12:56 pm

Lexicon Pharmaceuticals will present clinical study results for LX9211, a non-opioid treatment for diabetic peripheral neuropathic pain, and INPEFA, a recently approved drug for heart failure, at the American Diabetes Association's 83rd Scientific Sessions.

Portfolio Pulse from Happy Mohamed

June 20, 2023 | 12:17 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.